Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Ipsen has entered an exclusive global licensing agreement with Foreseen Biotech for FS001, a potentially first-in-class ADC.

Jul 14, 2024 - 04:00

Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Ipsen has entered an exclusive global licensing agreement with Foreseen Biotech for FS001, a potentially first-in-class ADC.

Read the original article

Tags:

Previous Article

NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

FDA grants fast track designation to AskBio’s AB-1005 for PD

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Colorado could cap payments for Amgen’s Enbrel

Colorado could cap payments for Amgen’s Enbrel

Feb 23, 2024

STAT+: Hospitals race to adopt generative AI, even as regulators struggle to keep up with the risks

STAT+: Hospitals race to adopt generative AI, even as r...

Feb 21, 2024

Epigenetic drugs show 375% increase in Series A venture financing in 2024

Epigenetic drugs show 375% increase in Series A venture...

Sep 26, 2024